1Sem.·

$ABBV (+1,32 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (+0,4 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commentaires

Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
9
image de profil
If AbbVie goes down even further, I might spontaneously get in today ^^
3
Voir toutes les 4 autres réponses
image de profil
Am in
2
image de profil
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
2
image de profil
stupid :(
image de profil
Gut :)
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
Participez à la conversation